Olomorasib for advanced colorectal cancer with a KRAS G12C mutation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing an oral medication called olomorasib for people with advanced colorectal cancer that has a specific gene change (KRAS G12C). It may be a good option if you have not yet had treatment for cancer that has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer that is stage III or IV and cannot be removed with surgery or cured with radiation.
- Your tumor must have a specific change called KRAS G12C (your doctor can test for this).
- You should have not yet received any drug treatment for cancer that has spread, except possibly 1–2 cycles of FOLFOX if needed right away.
- You need to be able to swallow capsules and be in fairly good health (able to do light activity, like walking).
- You cannot have untreated cancer that has spread to the brain, or have inflammatory bowel disease that needs medication.
- You must not have another cancer that is growing or that needed treatment in the past 2 years, and cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
This trial is testing a combination of two targeted drugs (panitumumab and sotorasib) with a chemotherapy drug (5-fluorouracil) for people with advanced colorectal cancer that has a specific KRAS G12C mutation and who cannot receive stronger chemotherapy. It aims to see if this treatment can help control the cancer.
This trial tests a new combination of drugs (sotorasib, panitumumab, and FOLFIRI) against the standard treatment for colorectal cancer that has spread. It's for people whose tumor has a specific KRAS G12C mutation and who have not had chemotherapy before for advanced disease.
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.